Vectorious Medical Technologies developed the V-LAP, the world's first in-heart microcomputer - enabling optimal treatment for heart disease patients, increasing their quality of life and life expectancy. The V-LAP sensory implant is the first digital, wireless, battery-less device that can communicate from deep within the body. It monitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration. Vectorious' V-LAP received the FDA's Breakthrough Device Designation for heart failure. Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2022.